For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study of Memory and Thinking Problems Associated with Alzheimer's Disease
The purpose of this study is to test if an experimental drug called AMX0035 is safe and helpful to people with memory and thinking problems associated with Alzheimer’s disease (AD). Study treatment (AMX0035 or placebo) will be assigned randomly. Nationwide, 50 participants will be recruited for this study. At Rush University Medical Center we expect to recruit up to 16 participants.
In order to participate you must meet the following criteria:
- Are 55-89 years old.
- Have a diagnosis of mild cognitive impairment (MCI) or Alzheimer’s disease (AD).
- Have an individual who knows you well willing to serve as your study partner.
You will be excluded from the study if any of the following criteria apply to you:
- Are unable or unwilling to complete all study activities (such as MRI scans and lumbar punctures).
- Have other medical conditions, illnesses or diseases that could interfere with study participation.
This is a partial list of inclusion and exclusion criteria.